High Dose Chemotherapy and Hematopoietic Progenitor Cell Transplantation for Breast Cancer
暂无分享,去创建一个
[1] G. Hortobagyi. What is the role of high-dose chemotherapy in the era of targeted therapies? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Thiel,et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Stockler,et al. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. , 2004, The Lancet. Oncology.
[4] M. Marangolo,et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999 , 2003, Bone Marrow Transplantation.
[5] R. Gray,et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. , 2003, The New England journal of medicine.
[6] G. Elfenbein. Stem-cell transplantation for high-risk breast cancer. , 2003, The New England journal of medicine.
[7] S. Rodenhuis,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. , 2003, The New England journal of medicine.
[8] Y. Nieto. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. , 2003, Haematologica.
[9] E. Shpall,et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Berry,et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Dancey,et al. A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study , 2001 .
[12] P. Pedrazzoli,et al. Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell transplantation as a therapeutic option for breast cancer. , 2001, Haematologica.
[13] S. Martino,et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.
[14] P. Pedrazzoli,et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Baynes,et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. , 2000, The oncologist.
[16] J. Armitage,et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. , 1999, JAMA.
[17] R. Vij,et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Gehan,et al. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma , 1999, Cancer.
[19] E. Shpall,et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Pater,et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Luini,et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Hortobagyi,et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Schmitz,et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.
[24] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[25] C. Gisselbrecht,et al. Dose intensive therapy in breast cancer. , 1992, Bone marrow transplantation.
[26] R. Bast,et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Shea,et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.